Regenxbio Inc
$ 6.08
-11.63%
05 Jun - close price
- Market Cap 314,322,000 USD
- Current Price $ 6.08
- High / Low $ 6.91 / 6.00
- Stock P/E N/A
- Book Value 0.41
- EPS -5.60
- Next Earning Report 2026-08-06
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.38 %
- ROE -1.96 %
- 52 Week High 16.19
- 52 Week Low 5.46
About
REGENXBIO Inc., a clinical-stage biotechnology company, offers candidate gene therapy products to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies intended to affect disease. The company is headquartered in Rockville, Maryland.
Analyst Target Price
$23.82
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-14 | 2026-03-05 | 2025-11-06 | 2025-08-07 | 2025-05-12 | 2025-03-13 | 2024-11-06 | 2024-08-01 | 2024-05-08 | 2024-02-27 | 2023-11-08 | 2023-08-02 |
| Reported EPS | -1.72 | -1.3 | -1.2 | -1.38 | 0.12 | -1.01 | -1.17 | -1.05 | -1.34 | -1.43 | -1.41 | -1.66 |
| Estimated EPS | -1.41 | -0.7194 | -1.3 | -1.05 | 0.34 | -1.0844 | -1.1 | -1.31 | -1.26 | -1.27 | -1.52 | -1.21 |
| Surprise | -0.31 | -0.5806 | 0.1 | -0.33 | -0.22 | 0.0744 | -0.07 | 0.26 | -0.08 | -0.16 | 0.11 | -0.45 |
| Surprise Percentage | -21.9858% | -80.7061% | 7.6923% | -31.4286% | -64.7059% | 6.8609% | -6.3636% | 19.8473% | -6.3492% | -12.5984% | 7.2368% | -37.1901% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-06 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | 0.34 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: RGNX
2026-06-06 12:50:00
This article analyzes Regenxbio Inc. (NASDAQ: RGNX), indicating weak near and mid-term sentiment but a neutral long-term outlook. It highlights elevated downside risk due to a lack of additional long-term support signals. The analysis provides specific trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with entry, target, and stop-loss prices, along with multi-timeframe signal analysis for different horizons.
2026-06-05 19:39:55
H.C. Wainwright has reiterated its Buy rating on Regenxbio (RGNX.US) but cut its price target to $26. This adjustment reflects a continued positive outlook on the company's prospects despite a revised valuation. Investors should note the maintained "Buy" recommendation alongside the lowered price target.
2026-06-05 19:39:55
HC Wainwright & Co. has maintained a 'Buy' rating for Regenxbio (RGNX) but lowered its price target from $30 to $26, reflecting a cautious outlook amidst market challenges. Despite being considered 52% undervalued by GuruFocus, RGNX has a low GF Score™ of 58 and concerning financial strength and profitability ratings. Insider selling activity also indicates potential concerns about near-term performance.
2026-06-04 17:09:57
JPMorgan Chase & Co. and its affiliates have reported a 4.4% beneficial ownership stake in REGENXBIO Inc. (NCUSIP 75901B107), amounting to 2,279,362 shares. This disclosure was made in an amended Schedule 13G/A filing, indicating passive investment intent. The filing details specific voting and dispositive powers held by multiple JPMorgan entities.
2026-06-03 12:39:37
REGENXBIO Inc. has launched an option-for-option exchange program targeting non-executive employees. The offer allows eligible employees to exchange certain stock options granted under the 2015 Equity Incentive Plan for replacement options under the 2025 Equity Incentive Plan. As of May 27, 2026, approximately 2.9 million eligible options with grant dates before July 1, 2024, and an exercise price of at least $18.00 are outstanding.
2026-06-03 11:39:37
REGENXBIO Inc. reported the results of its 2026 annual stockholder meeting, where investors approved the election of three Class II directors, ratified PricewaterhouseCoopers LLP as the independent auditor, and endorsed the compensation of named executive officers. Stockholders also approved a stock option exchange program exclusively for non-executive employees but rejected a similar proposal for executive employees. The non-executive option exchange program, commenced on June 3, 2026, allows eligible employees to swap underwater options for a reduced number of new options at fair market value.
